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MAD2Earlier studies showed that 2-methoxyestradiol (2ME2), an endogenous nonpolar metabolite of estradiol-
17β, is a strong inducer of G2/M cell cycle arrest (based on analysis of cellular DNA content) in human cancer
cell lines. The present study sought to investigate the molecular mechanism underlying 2ME2-induced cell
cycle arrest. We found that 2ME2 can selectively induce mitotic prometaphase arrest, but not G2 phase arrest,
in cultured MDA-MB-435s and MCF-7 human breast cancer cells. During the induction of prometaphase
arrest, there is a time-dependent initial up-regulation of cyclin B1 and Cdc2 proteins, occurring around
12–24 h. The strong initial up-regulation of cyclin B1 and Cdc2 matches in timing the 2ME2-induced
prometaphase arrest. The 2ME2-induced prometaphase arrest is abrogated by selective knockdown of
cyclin B1 and Cdc2, or by pre-treatment of cells with roscovitine, an inhibitor of cyclin-dependent kinases,
or by co-treatment of cells with cycloheximide, a protein synthesis inhibitor that was found to suppress
the early up-regulation of cyclin B1 and Cdc2. In addition, we provided evidence showing that MAD2 and
JNK1 are important upstream mediators of 2ME2-induced up-regulation of cyclin B1 and Cdc2 as well as
the subsequent induction of mitotic prometaphase arrest. In conclusion, treatment of human cancer cells
with 2ME2 causes up-regulation of cyclin B1 and Cdc2, which then mediate the induction of mitotic
prometaphase arrest.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
2-Methoxyestradiol (2ME2), a well-known endogenous derivative
of estradiol-17β (E2), is biosynthesized by catechol-O-methyltransferase
using 2-hydroxy-E2 as substrate and S-adenosyl-L-methionine asmethyl
donor [1,2]. Studies have shown that 2ME2 at pharmacological concen-
trations has a strong growth-inhibitory effect in a variety of human
cancer cell lines in culture [3–12]. This estrogen metabolite has also
been tested in a number of preclinical as well as clinical studies for
its potential usefulness in the treatment of solid tumors [17–22].
Since the anti-cancer activity of 2ME2 is not shared by E2, it is unlikely
that such actions occur through itsmetabolism to estrogenic derivatives.
To understand its cellular mechanism of actions, a number of earlier
studies have investigated its effect on cell cycle changes and cell death
in cultured human cancer cells [6,10–16,23–25]. It has been consistently
observed that the induction of G2/M cell cycle arrest (based on ﬂow
cytometric analysis of the cellular DNA content) is a predominant initial4,5-dimethylthiazol-2-yl)-2,5-
ycloheximide; Cdc2, cell divi-
itotic arrest deﬁcient 2
y, Toxicology and Therapeutics,
r, MS-1018, room HLSIC-4061,
1 913 588 9842; fax: +1 913
l rights reserved.cellular change in 2ME2-treated cells [11,12,14–16,23,24], and this
change is subsequently followed by increased apoptotic cell death
[13–16,23,24]. It has been suggested that the ability of 2ME2 to induce
G2/M cell cycle arrest is associated with its ability to interact with mi-
crotubules, thereby disrupting normal microtubule functions [26,27].
In line with this suggestion, the G2/M cell cycle arrest induced by
2ME2 can also be induced by other well-known anti-microtubule
agents, such as nocodazole, paclitaxel, and vinblastine. These microtu-
bule inhibitors can bind to tubulins ormicrotubules and suppressmicro-
tubule dynamics and functions, subsequently inducing G2/M cell cycle
arrest as well as apoptotic cell death [28–32].
In a normal cell cycle, the activation of the cyclin B1/Cdc2 function
plays a critical role in regulating the transition of cells from the G2
phase to mitotic M phase [33]. Generally, cells with a suppressed cyclin
B1/Cdc2 activity would tend to be arrested in the G2 phase, whereas
cells with an up-regulated cyclin B1/Cdc2 activity would be favored to
enter and proceed through mitosis [33]. Notably, some of the earlier
studies have probed the changes of some of the cell cycle regulatory
proteins (such as cyclin B1 and Cdc2) following treatment of human
cancer cells with 2ME2. While one study reported that the cellular
level of cyclin B1 is down-regulated in MCF-7 human breast cancer
cells treatedwith 2ME2 [34], other studies using different human cancer
cell lines showed an increased level of cyclin B1 and/or Cdc2 [11,35,36].
The observation of an increased cyclin B1/Cdc2 level during the occur-
rence of G2/M arrest in 2ME2-treated cells is rather intriguing, because
1307H.J. Choi, B.T. Zhu / Biochimica et Biophysica Acta 1823 (2012) 1306–1315this phenomenon is different from the known regulatory functions of
cyclin B1 and Cdc2 during a normal cell cycle.
In the present study, therefore, we sought to further study the
mechanism underlying 2ME2-induced G2/M cell cycle arrest in human
breast cancer cells by focusing on the cell cycle regulatory proteins at
theG2/Mboundary.We found that 2ME2 only selectively inducesmitotic
prometaphase arrest, but not G2 phase arrest. During the induction
of prometaphase arrest by 2ME2, there is a time-dependent early
up-regulation of cyclin B1 and Cdc2 proteins. A series of experiments
were then conducted to demonstrate that the cyclin B1/Cdc2 up-
regulation in 2ME2-treated breast cancer cells contributes critically
to the selective development of prometaphase arrest and some of the
cellular morphological characteristics observed. In addition, we also
showed that MAD2 and JNK1 are important upstream mediators0
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Fig. 1. Effect of 2ME2 on cell cycle arrest. (A and B) Changes in the combined G2 and M cell po
with 1 or 2 μM 2ME2 for 24 h (A), or with 2 μM 2ME2 for 12, 24, 48, and 72 h (B). Treatment
and analyzed by ﬂow cytometry. Each bar is the mean±S.D. (N=6 replicates). * Pb0.05
(stained with Hoechst-33342) following treatment with 2 μM 2ME2 or 250 nM nocodazole
and ﬂuorescence microscopes (×200 magniﬁcation). The arrow points the cell shown in
arrested MDA-MB-435s and MCF-7 cells following treatment with 2ME2 (2 μM). Each bar
was based on counting ≥200 nuclei in each treatment group. * Pb0.05 versus the control.responsible for the up-regulation of cyclin B1 and Cdc2 and the induction
of prometaphase arrest.
2. Materials and methods
2.1. Chemicals and reagents
2ME2, nocodazole, roscovitine, cycloheximide, and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
were obtained from Sigma (St. Louis, MO). The JNK1/2 inhibitor
SP600125 was obtained from Calbiochem (La Jolla, CA). The anti-c-Jun
NH2-terminal kinase 1/2 (JNK1/2) antibody was obtained from
Biosource (Camarillo, CA). Anti-p-c-jun, anti-Cdc2 (Cdk1), anti-Cdc2
(Try), anti-Cdc2 (Thr161), anti-cyclin B1, anti-Cdk2, anti-Cdc25C,MDA-MB-435s
MCF-7
 (h)
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(h)
* *
*
*
*
Noco 0 12 24 48 72
6 12 24 48 72
pulations following treatment with 2ME2. MDA-MB-435s and MCF-7 cells were treated
with 250 nM nocodazole for 12 h was also tested for comparison. Cells were harvested
versus the corresponding control. (C) Morphology of cells arrested in prometaphase
at indicated time points. The morphology was viewed using both phase contrast (PC)
the enlarged inset. (D) Quantitative data of the relative population of prometaphase-
is the mean±S.D. value from triplicate determinations, and each value (percentage)
1308 H.J. Choi, B.T. Zhu / Biochimica et Biophysica Acta 1823 (2012) 1306–1315anti-Cdc25A, and anti-GAPDH antibodies were purchased from Cell
Signaling Technology (Beverly,MA). Anti-MAD2 antibodywas obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). The sources of other
materials are described elsewhere [16].
2.2. Cell culture, MTT assay, and ﬂow cytometric analysis
The culture conditions of MCF-7 and MDA-MB-435s human breast
cancer cells (obtained from ATCC, Manassas, VA)were described earlier
[16]. For treatment of cells with 2ME2, a stock solution of 2ME2 (5 mM
in 200-proof ethanol) was diluted in the culture medium immediately
before addition. Following the treatment, theMTT assaywas performed
to determine cell viability according to the methods described earlier
[16]. For ﬂow cytometric analysis, cells were harvested and treated as
described previously [16]. The analysis was performed on a model BD
LSR II ﬂow cytometer (BD Bioscience, San Jose, CA).
2.3. Nuclear and cytosolic extracts
The nuclear and cytosolic fractions were prepared using the sub-
cellular fractionation kit obtained from Biovision (Mountain View,
CA) by following the instructions of the manufacturer. Brieﬂy, cells
were suspended in hypotonic buffer and lysed with the proprietary
detergent included in the kit. Samples were centrifuged at 800 g for
10 min at 4 °C. The supernatant was collected, centrifuged 5 min at
16,000 g to remove any remaining nuclei, and then transferred to a
new microtube (cytosolic protein fraction). The original pellet was
re-suspended in the nuclear extraction buffer and then incubated
on ice for 40 min with occasional vortexing. After salt extraction,
the nuclear suspension was centrifuged at 16,000 g for 10 min, and
the supernatant was collected and stored at−80 °C as nuclear extract.Fig. 2. Effect of 2ME2 on the cellular levels of cyclin B1, Cdc2, Cdk2 and cdc25C proteins. (A) MD
indicated. Total cell lysates were prepared, and an equal amount of protein lysates was elec
nitrocellulose membrane. The protein level was determined using speciﬁc antibodies on an enh
or 250 nM nocodazole for different lengths of time as indicated. Total cell lysates were analyze
blotting. (D) MDA-MB-435s and MCF-7 cells were treated with 2 μM 2ME2 for 12 h, and the to
by Western blotting using antibodies speciﬁc for each of the phosphorylated proteins.2.4. Western blotting
For Western blotting, cells were washed and then suspended in
100 mL lysis buffer, and the amount of proteins was determined. Pro-
teins were separated by 10% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and electrically transferred to a polyvinylidene diﬂuoride
membrane (Bio-Rad). After blocking the membrane using 5% skim
milk, target proteins were immunodetected using speciﬁc antibodies.
Thereafter, the horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG was applied as the secondary antibody, and the positive bands
were detected using the AmershamECL PlusWestern blotting detection
reagents (GE Healthcare, Piscataway, NJ).2.5. Small interfering RNA (siRNA) treatment
The role of JNK1 in mediating 2ME2 actions was examined using
the JNK1-siRNA (siJNK1) to silence its gene. The siJNK1 (catalog no.
AM16704) and the negative control siRNA (siCon; catalog no. AM4611)
were obtained from Ambion (Austin, TX). Similarly, the role of cyclin
B1, Cdc2, and MAD2 in mediating 2ME2 actions was examined using the
following speciﬁc siRNAs (obtained from Santa Cruz), namely, cyclin B1-
siRNA (sicyclin B1; catalog no. sc-29284), Cdc2-siRNA (siCdc2; catalog
no. sc-29252), andMAD2-siRNA(siMAD2; catalogno. sc-35837), to selec-
tively silence their expression.MDA-MB-435s andMCF-7 cellswere seed-
ed 24 h earlier and reached a density of 30–50% conﬂuency at the time of
transfection. Sixty pmol of siJNK1 or 40 nmol of sicyclin B1, siCdc2,
siMAD2, or siCon was used for transfection with Lipofectamine 2000
(Invitrogen; Carlsbad, CA). Transfected cells were maintained in culture
for 2 days before harvesting and further analyses. The efﬁciency of the
siRNA knockdown for each gene was determined byWestern blot analy-
sis of its protein product.A-MB-435s andMCF-7 cells were treated with 2 μM 2ME2 for different lengths of time as
trophoretically separated on the 10% SDS-polyacrylamide gel, and then transferred to a
anced chemiluminescence (ECL) apparatus. (B and C) Cells were treated with 2 μM 2ME2
d for the protein levels of cyclin B1, Cdc2, Cdk2, cyclin A, Cdc25C, and Cdc25A by Western
tal cell lysates were analyzed for the levels of p-Cdc2(Try15) and p-Cdc2(Thr161) proteins
Fig. 3. Effect of cyclin B1/Cdc2 knockdown on the development of 2ME2-induced
prometaphase arrest. (A) MCF-7 cells were treated with 2 μM 2ME2 for 12 h and then
immunostained with anti-cyclin B1 or anti-Cdc2 antibodies. Nuclear accumulation of
cyclin B1 (left panel) and Cdc2 (right panel) in 2ME2-treated cells that have developed
prometaphase arrest. (B) Subcellular localization of cyclin B1 and Cdc2 inMCF-7 cells dur-
ing 2ME2-induced prometaphase arrest (at 6, 12, and 24 h after treatment). Cytosolic and
nuclear extracts were prepared from 2ME2-treated cells, and cyclin B1 and Cdc2 proteins
were analyzed by Western blotting. (C, D, and E) MCF-7 cells were transfected with
sicyclin B1 and siCdc2 or siCon, and then treated with 2ME2 for 12 h. Total cell lysates
were analyzed by Western blotting for cyclin B1 and Cdc2 (C). The DNA content of the
cells was analyzed using ﬂow cytometry (D), and their gross nuclear morphology was ex-
amined underﬂuorescencemicroscopy (originalmagniﬁcation, ×200) after the cellswere
stained with Hoechst-33342 (E, left panel). The quantitative data for the prometaphase-
arrested cells (based on counting ≥200 nuclei in each treatment group) are shown in E
(right panel). Each bar is the mean±S.D. from triplicate measurements. * Pb0.05 versus
vehicle control; # Pb0.05 versus 2ME2 treatment.
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Many of the quantitative data were expressed as mean±S.D. Sta-
tistical signiﬁcance was determined using the analysis of variance
(ANOVA) followed by a multiple comparison test with a Bonferroni
adjustment. The P value of less than 0.05 is considered statistically
signiﬁcant.
3. Results
3.1. 2ME2 induces mitotic prometaphase arrest in human breast cancer
cells
First, we examined the effect of 2ME2 on cell cycle changes in two rep-
resentative humanbreast cancer cell lines (i.e., the ER-negativeMDA-MB-
435s cells and the ER-positiveMCF-7 cells) in culture. As shown in Fig. 1A,
2ME2 at 1 and 2 μMincreased the combinedG2/M cell populations (based
on ﬂow cytometric analysis) in a dose-dependent manner. Time-course
experiments showed that the 2ME2-induced G2/M arrest peaked around
12 h after treatment (Fig. 1B). Nocodazole, a prototypical microtubule
inhibitor [31], was tested as a positive control for comparison. Treatment
with 250 nM nocodazole for 12 h induced a similar G2/M cell cycle arrest
in these two cell lines (Fig. 1C).
Next, we examined the effect of 2ME2 on the nuclear morphological
changes after the cells were stained with Hoechst-33342. Typical mor-
phological features of untreatedMCF-7 cells at different stages ofmitosis
are shown in Fig. S1A. As shown in Fig. 1C, most of the cells treated with
2ME2 at 12 and 24 h had a round shape, and there was no concurrent
blebbing of the cell membranes, an indicator of cell death. However,
many of the treated cells exhibited gross chromosomal condensation
and segregation at 12 and 24 h, which are characteristic morphological
changes in cells blocked in prometaphase (Fig. S1B) [37]. There was a
close correlation between the time-dependent changes in 2ME2-induced
prometaphase arrest (Fig. 1D) and the combined G2/M cell population
(Fig. 1B). Notably, treatment of cells with nocodazole also induced simi-
lar morphological changes associated with prometaphase arrest (Fig. 1C,
D). These data showed, for the ﬁrst time, that 2ME2 selectively induces
mitotic prometaphase arrest, but not G2 phase arrest, in human breast
cancer cells in a time- and concentration-dependent manner.
3.2. Effect of 2ME2 on cell cycle regulatory proteins
To understand the mechanism by which 2ME2 induces mitotic
prometaphase arrest, we ﬁrst determined the expression of several
cell cycle regulatory proteins at the G2/M boundary, including cyclin
B1, cyclin A, Cdc2, Cdk2, Cdc25A, and Cdc25C. As shown in Fig. 2A
and B, the levels of cyclin B1 and Cdc2 expression in MDA-MB-435s
and MCF-7 cells were markedly increased at 3 h after 2ME2 treatment
and peaked between 12 and 24 h. After the initial 48 h (i.e., between
48 and 72 h), their levels decreased in a time-dependent manner. In
comparison, the initial increase in the ﬁrst 24 h was not observed
with cyclin A, Cdk2, and Cdc25A (data not shown), although similar
time-dependent decreases from 24 to 72 h were seen for these regu-
latory proteins (Fig. 2B). The Cdc25's mitotic migration band was
detected in MCF-7 cells at 6 and 12 h after 2ME2 treatment, and was
decreased after 24 h (Fig. 2A). Similarly, the levels of cyclin B1 and
Cdc2 in MCF-7 cells treated with nocodazole were also changed in a
comparable time-dependent manner (Fig. 2C).
It is known that the function of Cdc2 is regulated by its phosphoryla-
tion at Try15 (which results in inactivation) and Thr161 (which results
in activation). We found that while the phosphorylation at Thr161 (acti-
vation) wasmarkedly increased by 2ME2 treatment, the phosphorylation
at Try15 (inactivation) was decreased (Fig. 2D). Together, these data
show that 2ME2-induced Cdc2 activation includes both an increase in its
protein level and a favorable change in its phosphorylation patterns.3.3. Functional role of cyclin B1/Cdc2 up-regulation in 2ME2-induced
prometaphase arrest
It is known that aberrant accumulation of cyclin B1 and Cdc2 in the
nucleus of a cell will trigger chromosomal condensation and segrega-
tion [30]. Therefore, it is hypothesized that the up-regulation of cyclin
B1/Cdc2 may be associated with the development of prometaphase ar-
rest in 2ME2-treated cancer cells. To test this hypothesis,we ﬁrst probed
whether the early up-regulation of cyclin B1 and Cdc2 protein levels
contributes to the observed nuclear morphological changes in 2ME2-
treated cells, by examining the subcellular localization of these two pro-
teins in control and 2ME2-treated cells using immunoﬂuorescence
staining and Western immunoblotting. As shown in Fig. 3A, while the
1310 H.J. Choi, B.T. Zhu / Biochimica et Biophysica Acta 1823 (2012) 1306–1315levels of these two proteins were very low in the cytoplasm and nuclei
of vehicle-treated control cells, their levels were dramatically increased
in the nuclei of 2ME2-induced prometaphase cells (at 12 h) (Fig. 3A).
The levels of cyclin B1 and Cdc2were also increased in the nuclear frac-
tion in a time-dependent manner (Fig. 3B).
To provide more deﬁnitive evidence for the involvement of cyclin
B1 and Cdc2, next we employed the siRNA approach to selectively
knock down their expression in breast cancer cells. Twenty-four
hours after joint transfection with sicyclin B1 and siCdc2, cells were
treated with 2ME2. Double knockdown of cyclin B1 and Cdc2 abrogated
2ME2-induced up-regulation of cyclin B1 and Cdc2 (Fig. 3C), and this
change in cyclin B1 and Cdc2 levels was accompanied by signiﬁcant
reductions in G2/M arrest (based on ﬂow cytometric analysis; Fig. 3D)
and prometaphase arrest (based on morphological analysis; Fig. 3E)
when the cells were analyzed at 12 h after 2ME2 treatment. At 24 h
after 2ME2 treatment of these knockdown cells, the degree of cell
death (based on PI and annexin V double staining) was also markedly
reduced (data not shown).Fig. 4. Effect of roscorvitine on 2ME2-induced prometaphase arrest. (A and B) MCF-7 cells
2ME2 or 250 nM nocodazole for additional 12 h. Total cell lysates were analyzed by Weste
levels of cyclin B1 and Cdc2 are calculated according to their densitometry readings, whic
for 2 h with roscovitine (20 μM) and then treated in combination with 2 μM 2ME2 for add
is the mean±S.D. from triplicate measurements. (C, upper panel) Gross nuclear morphologi
The nuclear morphology was examined under ﬂuorescence microscopy (×200 magn
a prometaphase-arrested cell. (C, lower panel) Quantitation of prometaphase cells based
# Pb0.05 versus 2ME2 or nocodazole treatment.The functional relationship between 2ME2-induced cyclin B1 and
Cdc2 up-regulation and prometaphase arrest was also probed by using
roscovitine (a known inhibitor of cyclin-dependent kinases) and cyclo-
heximide (a protein synthesis inhibitor). As shown in Fig. 4A, treatment
with 20 μM roscovitine suppressed cyclin B1/Cdc2 up-regulation induced
by 2 μM 2ME2 or 250 nM nocodazole. While treatment of cells with
roscovitine (20 μM) alone slightly increased the combined G2/M cell
populations, co-treatment of roscovitine with 2ME2 strongly suppressed
the accumulation of the combinedG2/Mcell populations (Fig. 4B). Further
quantiﬁcation of the population of prometaphase-arrested cells showed
that treatment with roscovitine alone did not appreciably enhance
prometaphase arrest, but it dose-dependently suppressed 2ME2-induced
accumulation of prometaphase-arrested cells (Fig. 4C).
Pre-treatment of breast cancer cells with cycloheximide also strong-
ly prevented 2ME2-induced increases in cyclin B1 and Cdc2 levels
(Fig. 5A). Similarly, cycloheximide reduced 2ME2-induced mitotic
prometaphase arrest (52% to 3.3%; Fig. 5B). Notably, treatment of cells
with cycloheximide alone did not appreciably increase the populationwere pre-treated for 2 h with roscovitine (20 μM) and then further treated with 2 μM
rn blotting for cyclin B1 and Cdc2 protein levels (A, upper panel). The relative protein
h are normalized to GAPDH protein level (A, lower panel). (B) Cells were pre-treated
itional 12 or 72 h. Cells were harvested and analyzed using ﬂow cytometry. Each bar
cal changes in cells treated with a representative concentration (20 μM) of roscovitine.
iﬁcation) after the cells were stained with Hoechst-33342. The arrow points to
on counting 200 nuclei in each treatment group. * Pb0.05 versus vehicle control;
Fig. 5. Effect of cycloheximide (CHX) on 2ME2-induced promataphase arrest. Cells were pre-treated for 2 h with cycloheximide (1 μg/mL) and then treated for additional 12 h with
2 μM 2ME2. Total cell lysates were analyzed by Western blotting for cyclin B1 and Cdc2 protein levels (A, upper panel). The relative protein levels of cyclin B1 and Cdc2 were
calculated according to their densitometry readings, which were normalized to GAPDH protein level (A, lower panel). Each value is mean±S.D. from triplicate measurements.
* Pb0.05 versus vehicle control; # Pb0.05 versus 2ME2 treatment. The gross nuclear morphology was examined under ﬂuorescence microscopy (original magniﬁcation, ×200)
after the cells were stained with Hoechst-33342 (B, upper panel). The arrow points to a prometaphase-arrested cell. The quantitative data (B, lower panel) was based on counting
200 nuclei in each treatment group. Each bar is the mean±S.D. from triplicate determinations. * Pb0.05 versus vehicle control; # Pb0.05 versus 2ME2 treatment.
1311H.J. Choi, B.T. Zhu / Biochimica et Biophysica Acta 1823 (2012) 1306–1315of prometaphase-arrested cells (Fig. 5B), nor of cell populations in the
G1 or G2 or sub-G1 phases (data not shown).3.4. Role of JNK1 in 2ME2-induced prometaphase arrest
Earlier studies in human prostate cancer cells [11] and human
breast cancer cells [16] have shown that treatment with 2ME2 results
in increased phosphorylation of JNK. Here we sought to evaluate
whether JNK is involved in 2ME2-induced prometaphase arrest in
MDA-MB-435s and MCF-7 cells. As shown in Fig. 6A and B, treatment
of these cells with 2 μM 2ME2 induced, in a time-dependent manner,
the phosphorylation of JNK1, but not JNK2. The total JNK1 and JNK2
protein levels were not signiﬁcantly altered by 2ME2 treatment. A
marked increase in JNK1 phosphorylation was seen as early as
30 min in MCF-7 cells after 2ME2 treatment, and peaked at 60 min
(Fig. 6B).
To verify the role of JNK1 in 2ME2-induced G2/M arrest, we used the
siRNA approach to suppress JNK1 expression in these cells. Twenty-four
hours after transfection with the siJNK1 or the negative control siRNAs,
cells were treated with 2ME2 for additional 24 h. As shown in Fig. 6C,
knockdown of JNK1 abrogated 2ME2-induced increase in JNK1 and
c-jun phosphorylation compared to cells transfected with the control
siRNAs. Similarly, knockdown of JNK1 abrogated the 2ME2-induced
up-regulation of cylin B1 and Cdc2 as well as p-Cdc2 (Thr161) at 12 h
(Fig. 6D), suggesting that JNK1 phosphorylation contributes to 2ME2-
induced up-regulation of cyclin B1/Cdc2.
In addition, as shown in Fig. 6E, JNK1 knockdown inMCF-7 andMDA-
MB-435s cells reduced the degree of 2ME2-induced G2/M cell cycle
arrest, from 61.5% to 36.8% and from 67.9% to 40.4%, respectively, com-
pared to control siRNA-transfected cells. Notably, the reduction in the
population of prometaphase cells was more pronounced in cells with
JNK1 knockdown (from 48.0% to 11.0% and 54.0% to 9.8%, respectively)(Fig. 6F), compared to the reductions in the combined G2/M cell
populations.
3.5. MAD2 mediates 2ME2-induced cyclin B1/Cdc2 accumulation and
prometaphase arrest
Next, we examined whether MAD2 is involved in 2ME2-induced
cyclin B1/Cdc2 accumulation and JNK1 phosphorylation in mitotically-
arrested MCF-7 cells. We found that the MAD2 level in cells treated
with 2ME2 was not increased by the treatment (Fig. 7A). Next, siRNA
approach was used to selectively knock down the expression of MAD2.
Following transfection of cells with siMAD2, the cells were then treated
with 2ME2 and then harvested for Western blotting of p-JNK1/2, p-c-
jun, p-Cdc2 (Thr161), cyclin B1, and MAD2 protein levels. Surprisingly,
knockdown of MAD2 abrogated 2ME2-induced increases in JNK1 acti-
vation as well as the up-regulation of cyclin B1 and p-Cdc2 (Thr161)
when compared to control siRNA-transfected cells (Fig. 7A). Moreover,
MAD2 knockdown also abrogated 2ME2-induced prometaphase arrest
at 12 and 24 h (52% to 2% and 43% to 6%, respectively) (Fig. 7B). Together,
these observations show that the function of MAD2 is critically required
for these changes seen in 2ME2-treated breast cancer cells.
4. Discussion
In this study, we ﬁrst conﬁrmed earlier observations that 2ME2
can predominantly induce a combined G2/M arrest (based on ﬂow
cytometric analysis) in cultured human breast cancer cells. Further
analysis of the nuclear morphology showed that 2ME2 mainly induces
mitotic prometaphase arrest, but not G2 phase arrest, in these cells.
The predominant induction of prometaphase arrest by 2ME2 in cancer
cells is not surprising given that this estrogen metabolite was known
to have an anti-microtubule activity [26]. Apparently, the ability of
2ME2 to induce prometaphase arrest is not related to its residual
Fig. 6. 2ME2-induced activation of the JNK signaling pathway during the induction of prometaphase arrest. (A and B)MDA-MB-435s andMCF-7 cells wereﬁrst incubatedwith 2 μM2ME2
for the indicated lengths of time, and then the cellular extracts were subjected toWestern blotting of the levels of p-JNK1/2 and JNK1/2. The level of GAPDH protein was determined as a
loading control. (C and D)MDA-MB-435s andMCF-7 cells were ﬁrst transfectedwith siJNK1 or the negative control siRNAs, and theywere then treatedwith 2ME2 for additional 24 h (C)
or 12 h (D), respectively. p-JNK, c-jun, p21, cyclin B1, Cdc2, and p-Cdc2(Thr161) levels were determined byWestern blotting. (E and F)MDA-MB-435s andMCF-7 cells were transfected
with siJNK1 and the negative control siRNAs, and then treated with 2ME2 for additional 12 h. The DNA content of the cells was analyzed by ﬂow cytometry (E). The gross nuclear mor-
phologywas examined under ﬂuorescencemicroscopy after the cells were stainedwith Hoechst-33342, and the quantitative data (F) was based on counting 200 nuclei in each treatment
group. Each bar is a mean±S.D. from triplicate determinations. * Pb0.05 versus vehicle control; # Pb0.05 versus 2ME2 treatment.
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it induces a similar level of prometaphase arrest regardless of the es-
trogen receptor status of the cell lines tested.
In a normal cell cycle, the transition from G2 phase to mitotic phase is
triggered by the activation of the cyclin B1/Cdc2 complex. Cells with a
suppressed cyclin B1/Cdc2 activity would tend to be arrested in the G2
phase, whereas cellswith an elevated cyclin B1/Cdc2 activitywould be fa-
vored to enter and then proceed through mitosis [33]. The results of our
present study show that treatment of human breast cancer cells with
2ME2 (a microtubule inhibitor) not only causes a strong up-regulation
of cyclin B1 and Cdc2 protein levels, but also alters its phosphorylation
patterns. Collectively, these changes are expected to result in marked
increases in the functionality of the cyclin B1/Cdc2 complex. However,
under these conditions, a higher percentage of cells are actually found
to be selectively arrested in mitotic prometaphase; by contrast, the con-
trol cells that are not treated with 2ME2 and have lower cyclin B1/Cdc2
levels actually have far fewer cells arrested in the prometaphase.Evidently, these seemingly paradoxical changes are due to the presence
of 2ME2, which disrupts microtubule functions and, in turn, creates a
false signal in prometaphase cells that they do not have an adequate
cyclin B1/Cdc2 activity to proceed through mitosis. Consequently, cells
arrested in prometaphase would increase their cyclin B1 and Cdc2 levels
and also change the phosphorylation pattern of Cdc2, as cellular compen-
satory responses to 2ME2 treatment. As discussed below, the results of
this study provide strong support for the proposed novel concept that a
strong, early up-regulation of cyclin B1 and Cdc2 following 2ME2 treat-
ment contributes critically to the development of prometaphase arrest
as well as some of the characteristic morphological changes.
Earlier studies have shown that a rapid, excessive activation of the
cyclin B1-dependent Cdc2 in G2 phase cells can result in aberrant entry
into mitotic phase [38,39]. Moreover, premature nuclear accumulation
of cyclin B1 and Cdc2 can trigger chromosomal condensation and seg-
regation. The results of our present study show that the marked early
increase in cyclin B1 and Cdc2 protein levels is accompanied by rapid
Fig. 7. Effect of MAD2 knockdown on 2ME2-induced cyclin B1/Cdc2 up-regulation.
(A) MCF-7 cells were transfected with siMAD2 or the negative control siRNAs, and
then treated with 2ME2 for additional 24 h. The protein levels of p-JNK, c-jun, cyclin
B1, MAD2, and p-Cdc2(Thr161) were determined by Western blotting. (B) The degree
of 2ME2-induced prometaphase arrest in cells with or without MAD2 knockdown. The
quantitative value (percentage) was based on counting ≥200 nuclei in each treatment
group. Each bar is the mean±S.D. from three separate experiments. * Pb0.05 versus
vehicle control; # Pb0.05 versus 2ME2 treatment.
1313H.J. Choi, B.T. Zhu / Biochimica et Biophysica Acta 1823 (2012) 1306–1315nuclear accumulation of these two proteins, in conjunction with the
development of nuclear chromosomal condensation and segregation,
which are characteristic features of cells blocked in prometaphase.
Moreover, we showed that selective knockdown of cyclin B1 and
Cdc2 strongly reduces the severity of nuclear chromosomal condensa-
tion and segregation as well as prometaphase arrest in 2ME2-treated
cells. Similar reductions in nuclear chromosomal condensation and
segregation as well as prometaphase arrest are also observed in
2ME2-treated cells upon co-treatment with roscorvitine (an inhibitor
of the cyclin-dependent kinases) or with cycloheximide (a protein
biosynthesis inhibitor that was found to reduce the levels of both cy-
clin B and Cdc2 in 2ME2-treated cells). Based on these observations, it
is suggested that a stronger initial compensatory up-regulation of the
cyclin B1/Cdc2 level following 2ME2 treatment would result in a more
severe form of prometaphase arrest because higher cyclin B/Cdc2
levels likely would bring about a more severe degree of chromosomal
condensation and segregation. In line with this study, we observed
that when higher concentrations of 2ME2 are used, higher levels of
cyclin B1 and Cdc2 are induced (data not shown), which is accompa-
nied by a more severe form of prometaphase arrest.
Earlier studies with human breast cancer cells [16] or human pros-
tate cancer cells [11] have shown that treatment with 2ME2 results in
increased phosphorylation of JNK. In addition, it was also reported
that JNK inhibition can attenuate 2ME2-induced apoptosis in human
breast cancer cells [16]. In this study, we evaluated whether JNK isalso involved in 2ME2-induced prometaphase arrest in MDA-MB-
435s and MCF-7 cells. We showed that 2ME2 can induce, in a time-
dependent manner, the phosphorylation of JNK1, but not JNK2,
while the total JNK1/2 protein levels are not signiﬁcantly changed.
Knockdown of JNK1 abrogates 2ME2-induced up-regulation of cylin
B1 and Cdc2 as well as p-Cdc2 (Thr161), suggesting that JNK1 phos-
phorylation contributes to 2ME2-induced up-regulation of cyclin B1
and Cdc2. As expected, JNK1 knockdown also results in a reduction
in 2ME2-induced prometaphase arrest.
It is known that MAD2 is an essential member of the spindle check-
point system, which restrains the metaphase-to-anaphase transition.
This protein is present at unattached kinetochores and is essential to
execute a block in themetaphase-to-anaphase transitionwhen amicro-
tubule inhibitor is present [40]. In this study, we found that although
the MAD2 protein level is not increased by treatment with 2ME2, its
knockdown drastically diminishes 2ME2-induced JNK1 activation as
well as the subsequent up-regulation of cyclin B1 and Cdc2 and the de-
velopment of prometaphase arrest. Since we also showed that JNK1
knockdown abrogates 2ME2-induced up-regulation of cyclin B1/Cdc2
and prometaphase arrest, it is evident that JNK1 is a downstream target
of MAD2.
Notably, we observed that MAD2 knockdown produces a stronger
reduction in prometaphase-arrested cells than does the joint knockdown
of cyclin B1 and Cdc2. This observation is actually in agreement with the
mechanistic explanation developed here. First, we showed in this study
that MAD2 knockdown can reduce the levels of cyclin B1 and Cdc2. Sec-
ond, it is known that MDA2 knockdown can also directly facilitate the
procession of prometaphase cells through metaphase and anaphase
[40]. Therefore, combination of these two effects would jointly help
reduce the population of prometaphase-arrested cells, producing a stron-
ger reduction in prometaphase arrest compared to cyclin B1 and Cdc2
knockdown alone.
In this study, roscovitine was found to suppress 2ME2-induced
increases in cyclin B1 and Cdc2 levels. Flow cytometric analysis showed
that the combined G2/M cell population is increased following treat-
ment with roscorvitine alone, but the population of prometaphase
cells is only slightly increased. Our observation is in agreement with
an earlier study showing that roscorvitine blocks MCF-7 cells in the G2
phase [41]. However, when roscovitine is used in combination with
2ME2, it strongly suppresses 2ME2-induced accumulation of the G2/M
population as well as prometaphase cells. The dose-dependent effect of
roscorvitine in suppressing 2ME2-induced accumulation of both G2/M
and prometaphase populations is closely correlated with its ability to
suppress cyclin B1/Cdc2 up-regulation. Collectively, these data suggest
that roscorvitine, when used in combination with 2ME2, can keep cells
in the G2 phase and suppress cells from entering prometaphase through
inhibition of the cyclin B1/Cdc2 complex.
We found that co-treatment of cancer cells with cycloheximide and
2ME2 completely suppresses the development of mitotic arrest. This
effect is readily explained on the basis of our observation that cyclohex-
imide can suppress 2ME2-induced up-regulation of cyclin B1 and Cdc2.
Notably, the combination treatment of cells with cycloheximide and
2ME2 does not produce a stronger degree of cell death; instead, these
two agents antagonize the cytotoxicity of each another. This observa-
tion is intriguing and offers a mechanistic basis that these two classes
of agents should not be used together as a combination anticancer
regimen.
It is of interest to note that although ﬂow cytometric analysis
shows that the cells treated with 2ME2 or roscorvitine exhibit a sim-
ilar G2/M cell cycle arrest pattern, the true nature of their cell cycle ar-
rests is strikingly different, based on the comparisons made in this
study. While roscorvitine predominantly induces G2 phase arrest
(with minimal accumulation of prometaphase cells), 2ME2 predomi-
nantly induces prometaphase arrest, along with a reduction in the
G2 phase cell population. Similar to the observation made with ros-
corvitine, selective knockdown of cyclin B1 and Cdc2 also decreases
Fig. 8. Schematic explanation of the role of the early cyclin B1/Cdc2 up-regulation in
the development of prometaphase arrest in cancer cells treated with 2ME2.
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fect G2 phase cells. Based on the mechanistic explanation developed
in this study, these results are readily understood because chemical
inhibition or down-regulation of cyclin B1/Cdc2 would only block
those cells that have already completed the DNA replication in the
G2 phase and prevent them from entering mitosis. Consequently,
they would not produce signiﬁcant prometaphase arrest.
Based on the observations made in the present study, a novel
mechanistic explanation (schematically depicted in Fig. 8) is pro-
posed for the role of cyclin B1 and Cdc2 up-regulation in the in-
duction of mitotic prometaphase arrest in 2ME2-treated cells. The
presence of 2ME2 will cause disruption of microtubule formation in
prometaphase cells, which subsequently results in failure of the mi-
crotubules to attach to kinetochores on the chromosomes. The unat-
tached kinetochores will then be bound by the spindle checkpoint
protein MAD2. The binding of MAD2 at the kinetochores prevents
the progression from prometaphase to metaphase and further to ana-
phase. The occurrence of prometaphase arrest creates a feedback up-
regulation of the cyclin B1 and Cdc2 protein levels, partly mediated by
the actions of the kinetochore-bound MAD2 proteins. The rapid rise
in these two proteins in prometaphase cells followed by rapid nuclear
accumulation leads to the induction of the characteristic nuclear phe-
notypes. Following a prolonged prometaphase arrest, it is speculated
that the 2ME2-treated cells will undergo cell death via activation of
the intrinsic apoptotic pathways.Conﬂicts of interest
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